Highlights

• A Western Australian gold producer lifted its FY30 production outlook to 560–610koz on 21 September 2026, and its shares jumped 6.145%.
• A memory technology developer joined the S&P/ASX 200 the same day, with an Israeli substantial holder raising its stake to 8.07%.
• A hearing implant maker named a former Boston Scientific executive to its board on 18 September 2026 and exited the S&P/ASX 50.

Three ASX-listed companies closed higher on 21 September 2026, each carrying a different story. A gold miner raised its long-term production targets, a semiconductor memory developer began trading as a member of the benchmark S&P/ASX 200, and a global hearing implant maker bolstered its board with a veteran medical technology executive. Here is what each company announced and how its shares responded.

How the shares moved

• Ramelius (ASX: RMS): up AU$0.220 (6.145%) to AU$3.800, as the market responded to its upgraded outlook.
• Weebit Nano (ASX: WBT): up AU$0.160 (4.790%) to AU$3.500 on its first day in the ASX 200.
• Cochlear (ASX: COH): up AU$5.949 (4.443%) to AU$139.850, despite leaving the ASX 50.

Ramelius sets bigger gold ambitions

Western Australian gold miner Ramelius Resources released a refreshed four-year outlook on 21 September 2026, forecasting FY30 production of 560,000–610,000 ounces at an all-in sustaining cost of AU$2,100–2,400/oz. That is 11% above its October 2025 plan and roughly 205% higher than FY26 output. FY27 guidance sits at 205–225koz at AU$2,150–2,350/oz. Costs are rising too. The Mt Magnet plant expansion now carries an underlying bill of AU$280 million, up from AU$223 million, with Primero appointed to build a new 3Mtpa circuit due for commercial production in the March 2028 quarter. Ramelius says its growth is fully funded, backed by more than AU$1 billion in cash, gold and investments.

Weebit Nano steps into the ASX 200

Memory technology developer Weebit Nano entered the S&P/ASX 200 before the open on 21 September 2026, following S&P Dow Jones Indices' quarterly review announced on 4 September. Institutional appetite was already building: in a notice dated 16 September 2026, Israel's Meitav Investment House reported raising its holding from 16,645,743 shares (6.93%) to 19,413,743 shares (8.07%), after on-market purchases worth about AU$9.45 million.

Cochlear strengthens its medtech presence

Cochlear announced on 18 September 2026 that Professor Ian Meredith AM will join its board as an independent non-executive director, effective 1 December 2026. Meredith brings extensive medical technology experience, having previously held the position of Executive Vice President and Global Chief Medical Officer at Boston Scientific, where he was responsible for a portfolio of approximately 15,000 healthcare products. In the same index review, Cochlear and WiseTech Global were removed from the S&P/ASX 50, with Mineral Resources and NEXTDC taking their places.

The bigger picture

The three stocks rose for different reasons: an operational upgrade at Ramelius, growing institutional ownership at Weebit, and boardroom renewal at Cochlear. Only Ramelius's gain lines up directly with news released on the day. For Weebit and Cochlear, the filings provide context rather than a clear catalyst, leaving investors to judge whether the momentum holds once the rebalance settles.

Note- All data presented is based on information available at the time of writing.

Disclaimer for Kapitales Research

The materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au